Recent trends in anti-corruption enforcement in China

This article examines the impact of the surge in enforcement actions, particularly the GlaxoSmithKline (GSK) investigation and decision. It also provides a series of steps that can be taken in developing an appropriate corporate compliance strategy in China.

Unlock unlimited access to all Global Investigations Review content